Terms: = Leukemia AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954 AND Prognosis
288 results:
1. TCEB3 initiates ovarian cancer apoptosis by mediating ubiquitination and degradation of mcl-1.
Cai Y; Li Y; Xu Y; Yang W; Huang M
FASEB J; 2024 Apr; 38(8):e23625. PubMed ID: 38661028
[TBL] [Abstract] [Full Text] [Related]
2. MNDA expression and its value in differential diagnosis of B-cell non-Hodgkin lymphomas: a comprehensive analysis of a large series of 1293 cases.
Zhang LF; Zhang Y; Shui RH; Lu HF; Jiang WH; Cai X; Li XQ; Yu BH
Diagn Pathol; 2024 Apr; 19(1):60. PubMed ID: 38627702
[TBL] [Abstract] [Full Text] [Related]
3. Targeting Myeloid leukemia-1 in Cancer Therapy: Advances and Directions.
Deng H; Han Y; Liu L; Zhang H; Liu D; Wen J; Huang M; Zhao L
J Med Chem; 2024 Apr; 67(8):5963-5998. PubMed ID: 38597264
[TBL] [Abstract] [Full Text] [Related]
4. Effective Targeting of Melanoma Cells by Combination of mcl-1 and Bcl-2/Bcl-x
Peng Z; Gillissen B; Richter A; Sinnberg T; Schlaak MS; Eberle J
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542429
[TBL] [Abstract] [Full Text] [Related]
5. BCL-X
Jenkins LJ; Luk IY; Chionh F; Tan T; Needham K; Ayton J; Reehorst CM; Vukelic N; Sieber OM; Mouradov D; Gibbs P; Williams DS; Tebbutt NC; Desai J; Hollande F; Dhillon AS; Lee EF; Merino D; Fairlie WD; Mariadason JM
Cell Death Dis; 2024 Mar; 15(3):183. PubMed ID: 38429301
[TBL] [Abstract] [Full Text] [Related]
6. Broadening the horizon: potential applications of CAR-T cells beyond current indications.
Karsten H; Matrisch L; Cichutek S; Fiedler W; Alsdorf W; Block A
Front Immunol; 2023; 14():1285406. PubMed ID: 38090582
[TBL] [Abstract] [Full Text] [Related]
7. FBXW7 affects autophagy through mcl1 in oral squamous cell carcinoma.
Sun Y; Nie W; Qiu B; Yang Q; Zhao H
Oral Dis; 2023 Nov; 29(8):3259-3267. PubMed ID: 38055341
[TBL] [Abstract] [Full Text] [Related]
8. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.
Valent P; Akin C; Arock M; Gleixner KV; Greinix H; Hermine O; Horny HP; Ivanov D; Orfao A; Rabitsch W; Reiter A; Schulenburg A; Sotlar K; Sperr WR; Ustun C
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894806
[TBL] [Abstract] [Full Text] [Related]
9. Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-X
Beltrán-Visiedo M; Jiménez-Alduán N; Díez R; Cuenca M; Benedi A; Serrano-Del Valle A; Azaceta G; Palomera L; Peperzak V; Anel A; Naval J; Marzo I
Mol Oncol; 2023 Dec; 17(12):2507-2525. PubMed ID: 37704591
[TBL] [Abstract] [Full Text] [Related]
10. CDK9 Inhibitor Induces Apoptosis, Autophagy, and Suppression of Tumor Growth in Adult T-Cell leukemia/Lymphoma.
Kato N; Kozako T; Ohsugi T; Uchida Y; Yoshimitsu M; Ishitsuka K; Aikawa A; Honda SI
Biol Pharm Bull; 2023; 46(9):1269-1276. PubMed ID: 37661406
[TBL] [Abstract] [Full Text] [Related]
11. Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia.
Aroldi A; Mauri M; Ramazzotti D; Villa M; Malighetti F; Crippa V; Cocito F; Borella C; Bossi E; Steidl C; Scollo C; Voena C; Chiarle R; Mologni L; Piazza R; Gambacorti-Passerini C
J Cell Mol Med; 2023 Oct; 27(20):3053-3064. PubMed ID: 37654003
[TBL] [Abstract] [Full Text] [Related]
12. Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression).
Scheubeck G; Jiang L; Hermine O; Kluin-Nelemans HC; Schmidt C; Unterhalt M; Rosenwald A; Klapper W; Evangelista A; Ladetto M; Jerkeman M; Ferrero S; Dreyling M; Hoster E
Leukemia; 2023 Sep; 37(9):1887-1894. PubMed ID: 37495776
[TBL] [Abstract] [Full Text] [Related]
13. Celastrol impairs tumor growth by modulating the CIP2A-GSK3β-mcl-1 axis in gastric cancer cells.
Wu J; Ye F; Xu T
Aging (Albany NY); 2023 Jul; 15(14):6894-6904. PubMed ID: 37470692
[TBL] [Abstract] [Full Text] [Related]
14. Myeloid cell leukemia-1 as a candidate prognostic biomarker in cancers: a systematic review and meta-analysis.
Wang J; He Y; Yang C; Luo Q; Wang B
Expert Rev Anticancer Ther; 2023; 23(9):1017-1027. PubMed ID: 37467344
[TBL] [Abstract] [Full Text] [Related]
15. [Clinical Features and Outcomes of the Patients with B-Cell Chronic Lymphoproliferative Disease in the New Drug Era].
Xu CB; Hu M; Shen JZ; Xu HQ; Zheng RJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):722-729. PubMed ID: 37356932
[TBL] [Abstract] [Full Text] [Related]
16. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
Wang ML; Jurczak W; Zinzani PL; Eyre TA; Cheah CY; Ujjani CS; Koh Y; Izutsu K; Gerson JN; Flinn I; Tessoulin B; Alencar AJ; Ma S; Lewis D; Lech-Maranda E; Rhodes J; Patel K; Maddocks K; Lamanna N; Wang Y; Tam CS; Munir T; Nagai H; Hernandez-Ilizaliturri F; Kumar A; Fenske TS; Seymour JF; Zelenetz AD; Nair B; Tsai DE; Balbas M; Walgren RA; Abada P; Wang C; Zhao J; Mato AR; Shah NN
J Clin Oncol; 2023 Aug; 41(24):3988-3997. PubMed ID: 37192437
[TBL] [Abstract] [Full Text] [Related]
17. Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies.
Schorr C; Forindez J; Espinoza-Gutarra M; Mehta R; Grover N; Perna F
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176053
[TBL] [Abstract] [Full Text] [Related]
18. Heat shock factor 1 is a promising therapeutic target against adult T-cell leukemia.
Ishikawa C; Mori N
Med Oncol; 2023 May; 40(6):172. PubMed ID: 37165174
[TBL] [Abstract] [Full Text] [Related]
19. A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia.
Jonas BA; Hou JZ; Roboz GJ; Alvares CL; Jeyakumar D; Edwards JR; Erba HP; Kelly RJ; Röllig C; Fiedler W; Brackman D; Siddani SR; Chyla B; Hilger-Rolfe J; Watts JM
Hematol Oncol; 2023 Oct; 41(4):743-752. PubMed ID: 37086447
[TBL] [Abstract] [Full Text] [Related]
20. PD-L1 and mcl-1 markers and the relationship with prognostic characteristics of differentiated thyroid carcinoma.
Zantut-Wittmann DE; Barreto IS; Laus AC; Moreno DA; Moma CA; Maia FFR; Assumpção LVMD; Reis RM
Mol Cell Endocrinol; 2023 Jun; 570():111931. PubMed ID: 37072108
[TBL] [Abstract] [Full Text] [Related]
[Next]
